Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18180168 | 0.90 | HSD11B1 (0.54) | MAP4K4CYP17A1PSMB8AURKAHSD11B1 | |
| SCHEMBL3301424 | 0.90 | CYP17A1 (0.53) | MAP4K4CYP17A1AURKAHSD11B1RIPK2 | |
| SCHEMBL3311143 | 0.88 | DYRK2 (0.45) | MAP4K4CYP17A1PSMB8AURKASREBF2 | |
| SCHEMBL13394556 | 0.84 | CYP17A1 (0.54) | MAP4K4CYP17A1FFAR1DYRK2RIPK2 | |
| SCHEMBL25382759 | 0.82 | NPC1 (0.51) | MAP4K4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL30554088 | 0.82 | NPC1 (0.51) | MAP4K4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1846865 | 0.80 | RIPK2 (0.54) | AURKAHSD11B1FFAR1RIPK2KDR | |
| SCHEMBL1848638 | 0.80 | TRPV1 (0.52) | MAP4K4CYP17A1PSMB8SREBF2MEN1 | |
| SCHEMBL20865536 | 0.78 | CYP17A1 (0.68) | MAP4K4CYP17A1PSMB8HDAC3HDAC1 | |
| SCHEMBL12788367 | 0.74 | CYP17A1 (0.57) | MAP4K4CYP17A1PSMB8SREBF2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | MAP4K4 4649/4885CYP17A1 2101/4885PSMB8 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.